Table 1.
Demographic characteristics and presence of seborrheic dermatitis for patients with Parkinson disease in oral cannabidiol (CBD) and placebo treatment groups.
| Characteristic | CBD (n=26) | Placebo (n=27) | P valuea | ||||
| Age (years), mean (SE; SD) | 70.6 (1.2; 6.3) | 68.7 (1.4; 7.5) | .34 | ||||
| Gender, n (%) | .33 | ||||||
|
|
Female | 10 (38) | 7 (26) |
|
|||
|
|
Male | 16 (62) | 20 (74) |
|
|||
| Race | >.99 | ||||||
|
|
Asian | 0 (0) | 1 (4) |
|
|||
|
|
White | 26 (100) | 26 (96) |
|
|||
| Ethnicity | >.99 | ||||||
|
|
Hispanic or Latino | 1 (4) | 0 (0) |
|
|||
|
|
Not Hispanic or Latino | 25 (96) | 28 (96) |
|
|||
|
|
Not reported | 0 (0) | 1 (4) |
|
|||
| Employment | >.99 | ||||||
|
|
Disabled, permanently or temporarily | 1 (4) | 1 (4) |
|
|||
|
|
Retired | 20 (77) | 21 (78) |
|
|||
|
|
Working now | 4 (15) | 4 (15) |
|
|||
|
|
Partly retired | 1 (4) | 0 (0) |
|
|||
|
|
Retired, still involved in business | 0 (0) | 1 (4) |
|
|||
| Marital status | >.99 | ||||||
|
|
Divorced | 4 (15) | 4 (15) |
|
|||
|
|
Living with partner | 0 (0) | 1 (4) |
|
|||
|
|
Married | 21 (81) | 21 (78) |
|
|||
|
|
Widowed | 1 (4) | 1 (4) |
|
|||
| Duration of PDb (years), mean (SE; SD) | 6.6 (1.3; 6.8) | 4.6 (0.8; 4.0) | .19 | ||||
| Dosingc, mean (SD; SE) | N/Ad | ||||||
|
|
Final CBD dose (mg/day) | 187.50 (56.68; 11.12) | N/A |
|
|||
|
|
Final THCe dose (mg/day) | 6.28 (1.90; 0.37) | N/A |
|
|||
|
|
CBD level at final dose visit (ng/mL) | 49.29 (32.85; 6.44) | 0.00 (0.00; 0.00) |
|
|||
|
|
THC level at final dose visit (ng/mL) | 0.85 (0.91; 0.18) | 0.00 (0.00; 0.00) |
|
|||
| Time on study drug (days), mean (SD; SE) | 15.5 (1.8; 0.3) | 16.2 (1.6; 0.3) | .15 | ||||
aTwo-tailed t tests and Pearson χ2 or Fisher exact association tests.
bPD: Parkinson disease.
cBlood levels reflect 26 participants in the CBD group and 17 in the placebo group. Blood levels were not obtained for 3 participants in the CBD group and 2 in the placebo group.
dN/A: not applicable.
eTHC: tetrahydrocannabinol.